We hypothesized that IL-11 levels would strongly correlate with fibrosis and that these NMX compounds would effectively block the production of IL-11 and COL1 in patient-derived synovial fibroblasts, providing a basis for the preclinical rationale of a novel, targeted pharmacotherapy for AF. Here, IL11 is linked to atrial fibrillation.